Clinical Trials Logo

Clinical Trial Summary

Zoledronic acid selectively binds to bone and protects it from being metastasized by tumor cells. This study evaluates the safety and efficacy of zoledronic acid when added to standard therapies in breast cancer patients with metastatic bone lesions.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00372710
Study type Interventional
Source Novartis
Contact
Status Terminated
Phase Phase 3
Start date August 2002

See also
  Status Clinical Trial Phase
Completed NCT00375427 - Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions Phase 3